Table 2.
Clinical examples of senescence-associated biomarkers detected in organs and tissues of patients affected by age-related diseases.
| Organ/tissue | Senescence-associated biomarkers | Clinical references |
|---|---|---|
| Cardiovascular diseases | ||
| Aged vascular tissues | Telomeres length, SA-βGal, p16, and p21 | [170, 171] |
| Atherosclerosis | ||
| Systolic heart failure | ||
| Malignant tumors | ||
| Lung cancer | Telomeres length, SA-βgal | [172, 173] |
| Breast cancer | SA-βgal, p21, p16, DEP1, NTAL, EBP50, STX4, VAMP3, ARMX3, B2MG, LANCL1, VPS26A, and PLD3 | [174, 175] |
| Neuroblastoma | SA-βgal | [176] |
| Astrocytoma | SA-βgal | [177] |
| Mesothelioma | SA-βgal, p21 | [178] |
| Melanoma | SA-βgal, p16, and p21 | [179] |
| Prostate cancer | SA-βgal, Glb1, and HP1g | [154, 180] |
| Liver cancer | Telomeres length, SA-βgal | [181] |
| Colorectal cancer | Short telomeres | [182] |
| Fibrosis | ||
| Idiopathic pulmonary fibrosis | Telomeres length, IGFBP5, and SA-βgal | [183, 184] |
| Cystic fibrosis | Telomere length, p16 | [185] |
| Liver fibrosis | Telomere length, IGFBP-5, SA-β-gal, and p21 | [183, 186] |
| Renal fibrosis | p16 | [187, 188] |
| Neurological disorders | ||
| Alzheimer's disease | SA-β-gal | [189, 190] |
| Other diseases | ||
| Chronic obstructive pulmonary disease | Telomere length, p16, p21, and SA-βgal | [191, 192] |
| Pulmonary hypertension | p16, p21 | [192, 193] |
| Emphysema | Telomere length, IGFBP-3, IGFBP-rP1, p16INK4a, and p21 | [194, 195] |
| Benign prostatic hyperplasia | SA-βgal | [196, 197] |